Top Markets
#1 Pleasing Gold Pleasing Gold +1,510.61%
#2 Ontology Gas Ontology Gas +96.40%
#3 PulseChain PulseChain +61.85%
#4 Osmosis Osmosis +33.22%
#5 BOOK OF MEME BOOK OF MEME +32.36%
#6 Neiro Neiro +30.17%
#7 Collect on Fanable Collect on Fanable +29.35%
#8 Unit Pump Unit Pump +28.42%
#9 Pump.fun Pump.fun +28.42%
#10 Ontology Ontology +25.90%
Coin of the day
Pleasing Gold Pleasing Gold
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
LianBio LianBio

LianBio

LIAN
Rang in Aktien #25845
LianBio is a biopharmaceutical firm dedicated to advancing and commercializing... LianBio is a biopharmaceutical firm dedicated to advancing and commercializing medical treatments for a broad spectrum of conditions, encompassing cardiovascular, oncological, respiratory, ophthalmic, and inflammatory diseases. Its primary operational focus is in China and other Asian nations. The company's development pipeline features several investigational therapies: mavacamten, aimed at addressing obstructive and non-obstructive hypertrophic cardiomyopathy, as well as heart failure with preserved ejection fraction; TP-03, for the treatment of Demodex blepharitis; NBTXR3, targeting head and neck squamous cell carcinoma and other solid tumors; Infigratinib, for first-line and second-line cholangiocarcinoma and gastric cancers; BBP-398, also for solid tumors; Omilancor and NX-13, both indicated for ulcerative colitis (with Omilancor additionally for Crohn's disease); LYR-210, for chronic rhinosinusitis; and Sisunatovir, under investigation for respiratory syncytial virus. To further its drug candidates, LianBio has established strategic alliances, including a collaboration with Tarsus Pharmaceuticals, Inc. for the development and commercialization of TP-03, an eye solution for Demodex blepharitis. They also partner with Nanobiotix S.A. for NBTXR3, a radioenhancer designed to be directly administered into malignant tumors before standard radiation therapy. The company was founded in 2019 and is headquartered in Princeton, New Jersey.
Aktienkurs
$0.42275
Zuletzt synchronisiert: 2025-07-14
Marktkapitalisierung
$45.81M
Veränderung (1 Tag)
-0.89%
Veränderung (1 Jahr)
0.00%
Land
US
Handel LianBio (LIAN)

Kategorie

Healthcare
Gewinn für LianBio (LIAN)
Gewinn im 2026 TTM: 0
Laut den aktuellen Finanzberichten von LianBio betragen die aktuellen Gewinne des Unternehmens 0. Im Jahr 2026 erzielte das Unternehmen einen Gewinn von 0, gleich wie dem Gewinn im Jahr 2026, der 0 betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von LianBio von 2026 bis 2026
Gewinn am Ende jedes Jahres
Jahr Gewinn ändert
Nicht genügend Daten für die angegebenen Daten.
Gewinn ähnlicher Unternehmen oder Konkurrenten
Unternehmen Gewinn Gewinnunterschied Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US